Promising Alzheimer Antibody-Based Immunotherapy


Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.

Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a one-year study of monthly intravenous infusions of aducanumab that has shown a slowing of clinical decline measurements in Alzheimer disease. A phase III trial of the drug is ongoing.

Recent Videos
Martin Tolar, MD, PhD
Clifford R. Jack Jr., MD
David T. Jones, MD
Clifford R. Jack Jr., MD
 Lisa Mosconi, PhD
 Joel Salinas, MD, MBA
Lisa Mosconi, PhD
Charbel Moussa, MBBS, PhD
© 2024 MJH Life Sciences

All rights reserved.